DDX5-targeting fully human monoclonal autoantibody inhibits proliferation and promotes differentiation of acute promyelocytic leukemia cells by increasing ROS production.

Cell Death & Disease
Jing WuXiao-Ben Pan

Abstract

Acute promyelocytic leukemia (APL) therapy involves the compounds cytotoxic to both malignant tumor and normal cells. Relapsed APL is resistant to subsequent chemotherapy. Novel agents are in need to kill APL cells selectively with minimal toxicity. DDX5 has been recognized to be a novel target to suppress acute myeloid leukemia (AML). However, the role of DDX5 remains elusive in APL. Here a DDX5-targeting fully human monoclonal autoantibody named after 2F5 was prepared. It is demonstrated that 2F5 selectively inhibited APL cell proliferation without toxicity to normal neutrophil and tissues. Moreover, 2F5 was confirmed to induce G0/G1 phase arrest in APL cells, and promote APL cell differentiation combined with decreased DDX5 expression and increased reactive oxygen species (ROS) production. Knockdown of DDX5 by siRNA also inhibited proliferation, promoted cell differentiation and enhanced ROS production in APL cells. However, the ROS inhibitor reversed the effects of 2F5 on DDX5 and ROS in APL cells. Thus, we conclude that DDX5-targeting 2F5 inhibits APL cell proliferation, and promotes cell differentiation via induction of ROS. 2F5 showed the therapeutic value of fully human monoclonal autoantibody in APL, which provides a n...Continue Reading

References

Jun 19, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Hatice DuzkaleEmil J Freireich
Mar 18, 2008·Proceedings of the National Academy of Sciences of the United States of America·Lan WangZhu Chen
Sep 12, 2012·Immunobiology·Christian M Karsten, Jörg Köhl
Nov 14, 2012·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Hongmei ChenQiusheng Zheng
Jul 12, 2013·The New England Journal of Medicine·Francesco Lo-CocoUNKNOWN Study Alliance Leukemia
Jun 10, 2014·Cell Reports·Anthony MazurekBruce Stillman
Sep 18, 2014·The New England Journal of Medicine·Jacqueline Lehmann-CheHugues de Thé
Jul 15, 2015·Scientific Reports·Richard H WeisbartJames E Hansen
Sep 1, 2015·Journal of Cancer Research and Clinical Oncology·Song MaoJianhua Zhang
Oct 16, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rui WangYongkui Jing
Jan 31, 2016·Current Opinion in Hematology·Kelly J Norsworthy, Jessica K Altman
Apr 17, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L Cicconi, F Lo-Coco
Jul 29, 2016·Biologicals : Journal of the International Association of Biological Standardization·Ryo MisakiKazuhito Fujiyama
Jan 27, 2017·Journal of the National Cancer Institute·Wanpei CaiAlan Prem Kumar
Mar 2, 2017·The New England Journal of Medicine·Hagop KantarjianMax S Topp
Oct 5, 2017·The New England Journal of Medicine·Robert MarcusWolfgang Hiddemann
Mar 16, 2018·Journal of Experimental & Clinical Cancer Research : CR·Min ShaJunxing Huang
Apr 20, 2018·The Journal of Veterinary Medical Science·Priyanka SoniYoshihiro Kawaoka
Aug 15, 2019·British Journal of Haematology·Maximilian Stahl, Martin S Tallman

❮ Previous
Next ❯

Methods Mentioned

BETA
Surface Plasmon Resonance
flow cytometry
transfection
chip

Software Mentioned

ModFit LT
Image J

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.